Evaluating large-scale blood transfusion therapy for the current ebola epidemic in liberia

Journal of Infectious Diseases

Volumn 211, Issue 8, 2015, Pages 1262-1267

  Gutfraind, Alexander ^a,b   Meyers, Lauren Ancel ^c,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d SANTA FE INSTITUTE   (United States)

Author keywords

convalescent blood; dynamic model; Ebola virus disease; polyclonal antibody therapy; transfusion

Indexed keywords

ARTICLE; BLOOD ANALYSIS; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EPIDEMIC; FATALITY; FEASIBILITY STUDY; HEALTH IMPACT ASSESSMENT; HUMAN; LIBERIA; MATHEMATICAL MODEL; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS IDENTIFICATION; VIRUS TRANSMISSION; EBOLAVIRUS; EPIDEMIOLOGY; HEMORRHAGIC FEVER, EBOLA; HOSPITALIZATION; IMMUNOLOGY; PROCEDURES; THEORETICAL MODEL; VIROLOGY;

BLOOD TRANSFUSION; EBOLAVIRUS; EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; HOSPITALIZATION; HUMANS; LIBERIA; MODELS, THEORETICAL;

EID: 84926676487     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv042     Document Type: Article

References (40)

1. WHO Ebola Response Team. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371:1481-95.
2. Meltzer MI, Atkins CY, Santibanez S, et al. Estimating the future number of cases in the Ebola epidemic-Liberia and Sierra Leone, 2014-2015. MMWR Surveill Summ 2014; 63(suppl 3):1-14.
3. Galvani AP, Ndeffo-Mbah ML, Wenzel N, Childs JE. Ebola vaccination: if not now, when? Ann Intern Med 2014; 161:749-50.
4. Camacho A, Kucharski AJ, Funk S, Breman J, Piot P, Edmunds WJ. Potential for large outbreaks of Ebola virus disease. Epidemics 2014; 9:70-8.
5. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine-preliminary report. N Engl J Med 2014; doi:10.1056/NEJMoa1410863.
6. Strauss S. Biotech drugs too little, too late for Ebola outbreak. Nat Bio-technol 2014; 32:849-50.
7. World Health Organization. Statement on the WHO Consultation on potential Ebola therapies and vaccines. Geneva: World Health Organization, 2014.
8. Burnouf T, Emmanuel J, Mbanya D, et al. Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet 2014; 384:1347-8.
9. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemor-rhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999; 179(suppl 1):S18-23.
10. Takada A. Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever? Immunotherapy 2013; 5:441-3.
11. Saphire EO. An update on the use of antibodies against the filoviruses. Immunotherapy 2013; 5:1221-33.
12. Emond R, Evans B, Bowen E, Lloyd G. A case of Ebola virus infection. Br Med J 1977; 2:541.
13. Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2:695-703.
14. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends-is a paradigm change coming soon? In: Dimitrov AS, ed. Methods in Molecular Biology. Vol 525. New York: Humana Press, 2009:1-27.
15. Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci 2012; 109:5034-9.
16. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Geneva: World Health Organization, 2014.
17. Tapko JB, Toure B, Sambo LG. Status of blood safety in the WHO African Region: report of the 2010 survey. Geneva: World Health Organization, 2014.
18. World Health Organization. Experimental therapies: growing interest in the use of whole blood or plasma from recovered Ebola patients (convalescent therapies). Geneva: World Health Organization, 2014.
19. Pandey A, Atkins KE, Medlock J, et al. Strategies for containing Ebola in West Africa. Science 2014; 346:991-5.
20. Rivers CM, Lofgren ET, Marathe M, Eubank S, Lewis BL. Modeling the impact of interventions on an epidemic of Ebola in Sierra Leone and Liberia. PLoS Curr Outbreaks 2014; doi:10.1371/currents.outbreaks. fd38dd85078565450b0be3fcd78f5ccf.
21. Althaus CL. Estimating the reproduction number of Zaire ebolavirus (EBOV) during the 2014 outbreak in West Africa. PLoS Curr Outbreaks 2014; doi:10.1371/currents.outbreaks.91afb5e0f279e7f29e70560952 55b288.
22. Chowell G, Hengartner NW, Castillo-Chavez C, Fenimore PW, Hyman JM. The basic reproductive number of Ebola and the effects of public health measures: the cases of Congo and Uganda. J Theor Biol 2004; 229:119-26.
23. Nishiura H, Chowell G. Early transmission dynamics of Ebola virus disease (EVD), West Africa, March to August 2014. Rapid Commun 2014; 19:1-6.
24. Lekone PE, Finkenstaedt BF. Statistical inference in a stochastic epidemic SEIR model with control intervention: Ebola as a case study. Biometrics 2006; 62:1170-7.
25. Legrand J, Grais R, Boelle P, Valleron A, Flahault A. Understanding the dynamics of Ebola epidemics. Epidemiol Infect 2007; 135:610-21.
26. World Health Organization. Ebola response roadmap situation report for 29 October 2014. Geneva: World Health Organization, 2014.
27. van Hulst M, Sibinga CTS, Postma MJ. Health economics of blood transfusion safety-focus on sub-Saharan Africa. Biologicals 2010; 38:53-8.
28. Jacobs B, Mercer A. Feasibility of hospital-based blood banking: a Tan-zanian case study. Health Policy Plan 1999; 14:354-62.
29. Toner R, Pizzi L, Leas B, Ballas S, Quigley A, Goldfarb N. Costs to hospitals of acquiring and processing blood in the US. Appl Health Econ Health Policy 2011; 9:29-37.
30. McKay MD. Latin hypercube sampling as a tool in uncertainty analysis of computer models. In: Proceedings of the 24th Conference on Winter Simulation. New York: Association for Computing Machinery, 1992: 564.
31. World Health Organization. Ebola response roadmap situation report for 7 January 2015. Geneva: World Health Organization, 2015.
32. Bah EI, Lamah M-C, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 2015; 372:40-7.
33. Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013; 3365.
34. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
35. Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol 2014; 10:781-90.
36. Olinger GG, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci 2012; 109:18030-5.
37. First trials for Ebola treatments to start at MSF sites in December. Geneva, Switzerland: Médecins Sans Frontières, 2014. Available at: http://www.msf.org/article/first-trials-ebola-treatments-start-msf-sites-december. Accessed 18 November 2014.
38. Butler D. First trials of blood-based Ebola therapy kick off. Nature 2014; doi:10.1038/nature.2014.16564.
39. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196(suppl 2):S400-3.
40. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849-62.